Although the prognosis for the HER2-positive primary BC patients is worse than that for HER2-negative patients, anti-HER2 therapy with drugs such as Tra, a recombinant monoclonal antibody, achieved a 44% reduction in lethality compared with HER2-negative patients 4. The gene discussed is ERBB2; the disease is breast cancer.